Chamath Palihapitiya · Aug 23, 09:29 PM UTC
Bitcoin’s Best Week Since 2024
Historical operation · Retained
“On August 19, Moderna and Merck reported that their personalized cancer treatment succeeded in a Phase 3 trial, the first large late-stage study of a custom cancer therapy built using the same mRNA technology as Moderna’s COVID vaccine.”
Quoted source · Chamath Palihapitiya · 4 source segments
- [1] Chamath Palihapitiya
- [2] Chamath Palihapitiya
- [3] Chamath Palihapitiya
- [4] Chamath Palihapitiya
Model assessment
Moderna reported positive Phase 3 results for its personalized cancer vaccine, showing improved recurrence-free survival when combined with Keytruda. The stock surged 177% on the news, indicating a strong positive market reaction and improved expected fundamentals.
4 exact transcript citations